Prognostic test developed for E2F4 in breast cancer

By looking at the expression levels of downstream genes of the regulators in breast cancer, researchers have identified a gene signature in E2F4 that is predictive of estrogen receptor positive (ER+) breast cancer. The findings define a new opportunity for personalizing medicine for women whose Oncotype DX assay results classify them as of ‘intermediate-risk for recurrence.’ —> Read More Here


Leave a Reply

Your email address will not be published. Required fields are marked *